Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Dihydropteroate synthase (DHPS) from Plasmodium species is an essential bifunctional enzyme involved in de novo folate synthesis—a validated antimalarial drug target whose inhibition leads to parasite death but whose genetic plasticity underlies widespread antifolate resistance seen globally today. DHPS catalyzes the condensation of p-aminobenzoic acid (pABA) with 6-hydroxymethyldihydropterin pyrophosphate to form 7,8-dihydropteroate, a precursor for folate derivatives essential for DNA synthesis and cell division. Mutations in dhps confer resistance to sulfa drugs by reducing drug binding while retaining enzymatic function. The protein is expressed throughout all stages of the intraerythrocytic cycle.
Competitive inhibition of p-aminobenzoic acid (pABA) binding
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Dihydropteroate Synthase (Plasmodium) (DHPS).